DDInter1266 DDInter1409
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) binds {v} (Gene) UGT2B7
UGT2B7 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Sodium sulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Labetalol
Labetalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) binds UGT2B7 (Gene) and UGT2B7 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen (Compound) resembles Flurbiprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a